• Explore /
  • Poster
  • / EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.

EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.

Abstract Poster

Authors

null

Thomas Lillie

Grey Wolf Therapeutics, Abingdon, United Kingdom

Thomas Lillie , Ganessan Kichenadasse , Jia (Jenny) Liu , Tatiana Hernandez Guerrero , Emiliano Calvo , Haakan Jakobsson , Victor Moreno , Hui Kong Gan , Peter Joyce , Natalie Hyland , Mara Giovannetti , Tanya Palmer , Cheryl McAlpine , Daniel Green , Stefan N. Symeonides

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

ACTRN12623000108617

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 2589)

DOI

10.1200/JCO.2024.42.16_suppl.2589

Abstract #

2589

Poster Bd #

68

Abstract Disclosures

Similar Posters

First Author: Cristina Saura

Poster

2024 ASCO Annual Meeting

A phase I dose escalation trial of BCD-145 in patients with unresectable or metastatic melanoma.

A phase I dose escalation trial of BCD-145 in patients with unresectable or metastatic melanoma.

First Author: Fedor Kryukov

First Author: Álvaro Lassaletta

First Author: Monika Joshi